Recruiting

Testing a new medication to help stroke patients receiving emergency blood vessel treatment

Plain-English translation of NCT07513233 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing , a new medication that may help protect the brain after an acute ischemic stroke. You would receive this medication in addition to your standard emergency stroke treatment (a procedure called endovascular therapy, which restores blood flow to your brain). The study will test three different doses to find which one is safest and works best.

Acute ischemic stroke is a medical emergency that can cause lasting brain damage. While emergency procedures are the standard treatment to restore blood flow, researchers believe this medication could provide additional brain protection and improve recovery outcomes. This trial will determine if the medication is safe enough to study further in larger groups of patients.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have had an acute ischemic stroke confirmed by imaging, affecting specific blood vessels in your brain
you are eligible for and will receive emergency endovascular treatment within 24 hours
your stroke severity meets certain criteria (NIHSS score of 6 or higher and ASPECTS score of 6 or higher)
you were able to function independently before your stroke (modified Rankin Scale score of 0 to 1)

You likely don't qualify if…

you have any signs of bleeding in your brain on CT scan
you have a history of bleeding disorders or conditions that make bleeding more likely
you are allergic to contrast dye, anisodine hydrobromide, or have had severe reactions to similar medications
you have certain medical conditions that could be worsened by this medication, such as angle-closure glaucoma, urinary retention, or serious heart rhythm problems
you are pregnant, breastfeeding, or planning to become pregnant within 90 days

What participation looks like

If you qualify and enroll, you will receive the study medication intravenously (through an IV) twice daily for 7 consecutive days, starting before or during your emergency stroke procedure. Each dose will be diluted in saline and infused over about 60 minutes. The first dose is given before the blood vessel procedure, but the medication will not delay your emergency treatment. You will be monitored closely during and after treatment to ensure the medication is safe and tolerable at your assigned dose level.

AI-generated summary from trial data · Jul 13, 2026 · Not medical advice

Trial locations(2 sites)

China

Xuanwu Hospital, Capital Medical University, Beijing, None Selected

Anji County People's Hospital, Huzhou, Zhejiang